{"id":"aripiprazole-tablet","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Akathisia"},{"rate":"10-15%","effect":"Headache"},{"rate":"5-10%","effect":"Anxiety"},{"rate":"5-10%","effect":"Insomnia"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Weight gain"},{"rate":"5%","effect":"Tremor"},{"rate":"5%","effect":"Sedation"}]},"_chembl":{"chemblId":"CHEMBL2219425","moleculeType":"Small molecule","molecularWeight":"660.73"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aripiprazole differs from typical antipsychotics by acting as a partial agonist rather than a full antagonist at dopamine D2 receptors. This mechanism allows it to modulate dopamine activity—increasing it when levels are low and decreasing it when levels are high—thereby reducing both positive and negative symptoms of psychosis while potentially causing fewer extrapyramidal side effects. Its additional activity at serotonin receptors contributes to its efficacy in mood and behavioral disorders.","oneSentence":"Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and an antagonist at serotonin 5-HT2A receptors, which stabilizes dopamine and serotonin neurotransmission in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:36.490Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute manic or mixed episodes)"},{"name":"Major depressive disorder (adjunctive treatment)"},{"name":"Autism spectrum disorder (irritability)"}]},"trialDetails":[{"nctId":"NCT03238326","phase":"PHASE3","title":"Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2017-08-23","conditions":"Schizophrenia","enrollment":295},{"nctId":"NCT02431702","phase":"PHASE3","title":"A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-08","conditions":"Schizophrenia, Psychotic Disorders","enrollment":337},{"nctId":"NCT03874494","phase":"PHASE3","title":"Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2019-11-27","conditions":"Schizophrenia","enrollment":371},{"nctId":"NCT04789915","phase":"PHASE1","title":"Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis","status":"RECRUITING","sponsor":"Bjorn H. Ebdrup","startDate":"2021-05-26","conditions":"Psychosis, Negative Symptoms With Primary Psychotic Disorder","enrollment":46},{"nctId":"NCT05531591","phase":"PHASE4","title":"RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2019-08-01","conditions":"Depression, Dementia, Mild Cognitive Impairment","enrollment":87},{"nctId":"NCT02960763","phase":"PHASE4","title":"Optimizing Outcomes of Treatment-Resistant Depression in Older Adults","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-02-24","conditions":"Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression","enrollment":742},{"nctId":"NCT06589817","phase":"PHASE3","title":"A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"Chengdu Kanghong Pharmaceutical Group Co., Ltd.","startDate":"2024-10","conditions":"Acute Schizophrenia","enrollment":376},{"nctId":"NCT03423680","phase":"PHASE3","title":"A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression","status":"RECRUITING","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2018-02-22","conditions":"Depression, Bipolar","enrollment":390},{"nctId":"NCT06372210","phase":"NA","title":"A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2023-06-26","conditions":"Mental Disorder, Schizophrenia, Major Depressive Disorder","enrollment":54},{"nctId":"NCT06501339","phase":"PHASE4","title":"Maintenance Electroconvulsive Therapy (ECT) Versus Aripiprazole in Clozapine-resistant Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2024-08-10","conditions":"Clozapine Resistant Schizophrenia","enrollment":40},{"nctId":"NCT05402111","phase":"PHASE1","title":"A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-06-13","conditions":"Schizophrenia","enrollment":31},{"nctId":"NCT05542264","phase":"PHASE1","title":"A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-11-15","conditions":"Schizophrenia","enrollment":19},{"nctId":"NCT03198078","phase":"PHASE3","title":"Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2017-06-30","conditions":"Schizophrenia","enrollment":316},{"nctId":"NCT00202007","phase":"PHASE2","title":"Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2005-02","conditions":"Schizophrenia","enrollment":240},{"nctId":"NCT00261443","phase":"PHASE4","title":"A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-09","conditions":"Bipolar Disorder","enrollment":1270},{"nctId":"NCT05804721","phase":"PHASE1","title":"Bioequivalence Study of Aripiprazole From Apipe 10 mg Orally Disintegrating Tablets (Man. by: P&C Labs (Pellets & CR Products), Egypt) Versus Abilify 10 mg Orodispersible Tablets (Otsuka Pharmaceutical Netherlands B.V., Netherlands)","status":"COMPLETED","sponsor":"Genuine Research Center, Egypt","startDate":"2022-10-10","conditions":"Healthy","enrollment":29},{"nctId":"NCT05103410","phase":"PHASE4","title":"Impact of Aripiprazole on Postoperative Analgesia in Laparoscopic Hysterectomy","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2021-11-10","conditions":"Anesthesia, Analgesia, Hysterotomy","enrollment":80},{"nctId":"NCT00845026","phase":"PHASE2","title":"A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2009-03","conditions":"Schizophrenia","enrollment":261},{"nctId":"NCT05532254","phase":"PHASE1","title":"Bioequivalence Study of Aripiprazole in Healthy Adult Subjects Under Fasting Condition","status":"COMPLETED","sponsor":"Future University in Egypt","startDate":"2021-02-14","conditions":"Healthy Subjects","enrollment":31},{"nctId":"NCT01052103","phase":"PHASE2","title":"A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2010-01","conditions":"Schizophrenia","enrollment":167},{"nctId":"NCT00468130","phase":"NA","title":"Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children","status":"COMPLETED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2006-05","conditions":"Autism","enrollment":13},{"nctId":"NCT02091882","phase":"PHASE4","title":"Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2014-03-21","conditions":"Device Latency","enrollment":30},{"nctId":"NCT01111539","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-07-13","conditions":"Major Depressive Disorder (MDD)","enrollment":211},{"nctId":"NCT01418339","phase":"PHASE3","title":"Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-07-27","conditions":"Tourette's Disorder","enrollment":135},{"nctId":"NCT01418352","phase":"PHASE3","title":"Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-08-02","conditions":"Tourette's Disorder","enrollment":83},{"nctId":"NCT01416441","phase":"PHASE3","title":"Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-10-19","conditions":"Tourette's Disorder","enrollment":170},{"nctId":"NCT03892889","phase":"PHASE3","title":"A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2019-04-29","conditions":"Schizophrenia","enrollment":277},{"nctId":"NCT02088697","phase":"PHASE1","title":"A Bioequivalence Study of ASC-01 Placebo (Aripiprazole 0 mg/Sertraline 100 mg) and Sertraline Tablet in Healthy Male Subjects","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2013-12","conditions":"Healthy Volunteers","enrollment":50},{"nctId":"NCT03661983","phase":"PHASE4","title":"Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-10-13","conditions":"Tourette's Disorder (TD)","enrollment":36},{"nctId":"NCT04765085","phase":"NA","title":"Clinical Efficacy and Change of Life Quality Through Using the Comprehensive Behavioral Intervention Treatment for Tics","status":"WITHDRAWN","sponsor":"Children's Hospital of Fudan University","startDate":"2021-03","conditions":"Tic Disorders","enrollment":""},{"nctId":"NCT03289026","phase":"PHASE4","title":"Pharmacologic Treatment of Acute Episode of Schizophrenia: a Real World Study","status":"COMPLETED","sponsor":"Peking University","startDate":"2017-09-01","conditions":"Acute Schizophrenia Episode","enrollment":770},{"nctId":"NCT03172871","phase":"PHASE3","title":"Aripiprazole IM Depot in the Acute Treatment of Adults With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2017-05-15","conditions":"Schizophrenia","enrollment":436},{"nctId":"NCT04446234","phase":"PHASE4","title":"Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2021-05","conditions":"Schizophrenia","enrollment":350},{"nctId":"NCT03568500","phase":"PHASE4","title":"A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-05-21","conditions":"Schizophrenia, Schizoaffective Disorder, First Episode Psychosis","enrollment":44},{"nctId":"NCT03285503","phase":"PHASE1","title":"PK Study of Aripiprazole IM Depot for Chinese Patients With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2018-08-17","conditions":"Schizophrenia","enrollment":12},{"nctId":"NCT01446328","phase":"PHASE4","title":"Bergen Psychosis Project 2 - The Best Intro Study","status":"COMPLETED","sponsor":"Haukeland University Hospital","startDate":"2011-10","conditions":"Schizophrenia, Psychotic Disorders","enrollment":151},{"nctId":"NCT04234776","phase":"PHASE4","title":"Intramuscular Ketamine Versus Aripiprazole and Escitalopram in the Treatment of Resistant Depression","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2018-04-03","conditions":"Depressive Disorder","enrollment":88},{"nctId":"NCT03643159","phase":"PHASE4","title":"A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-06-28","conditions":"Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder","enrollment":2},{"nctId":"NCT01795105","phase":"","title":"ABF Tourette's Disorder Post Marketing Surveillance Study","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2012-06","conditions":"Tourette's Disorder","enrollment":692},{"nctId":"NCT02926976","phase":"NA","title":"The Optimal Treatment for Treatment-resistant Schizophrenia","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2016-11","conditions":"Schizophrenia","enrollment":150},{"nctId":"NCT03790085","phase":"EARLY_PHASE1","title":"Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals","status":"UNKNOWN","sponsor":"Tianjin Medical University General Hospital","startDate":"2018-09-01","conditions":"Schizophrenia, Major Depressive Disorder, Anxiety Disorders","enrollment":2700},{"nctId":"NCT02219009","phase":"PHASE2","title":"Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2014-08","conditions":"Schizophrenia, Mental Disorder, Nervous System Diseases","enrollment":67},{"nctId":"NCT02404532","phase":"PHASE4","title":"Substudy 'B' of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2015-02","conditions":"Device Latency","enrollment":30},{"nctId":"NCT02722967","phase":"PHASE2","title":"Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2016-03","conditions":"Schizophrenia, Major Depressive Disorder, Bipolar I Disorder","enrollment":49},{"nctId":"NCT00953745","phase":"NA","title":"Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":43},{"nctId":"NCT03232710","phase":"NA","title":"Bioequivalence Study of Bosiqing and ABILIFY Under Fasting/Fed Condition","status":"UNKNOWN","sponsor":"Chengdu Kanghong Pharmaceutical Group Co., Ltd.","startDate":"2017-06-26","conditions":"Bioequivalence","enrollment":66},{"nctId":"NCT00683852","phase":"PHASE3","title":"A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2008-09","conditions":"Major Depressive Disorder","enrollment":225},{"nctId":"NCT01795547","phase":"PHASE3","title":"Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2013-02","conditions":"Schizophrenia","enrollment":295},{"nctId":"NCT02501109","phase":"PHASE1","title":"Comparative Bioavailability Study of Aripiprazole 10 mg Oral Soluble Film vs Abilify® 10 mg Tablet in Healthy Volunteers","status":"COMPLETED","sponsor":"CMG Pharmaceutical Co. Ltd","startDate":"2015-10","conditions":"Schizophrenia","enrollment":36},{"nctId":"NCT02054702","phase":"PHASE3","title":"Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2014-02","conditions":"Schizophrenia","enrollment":97},{"nctId":"NCT02087579","phase":"PHASE1","title":"Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02","conditions":"Psychotic Disorders, Schizophrenia, Bipolar Disorder","enrollment":305},{"nctId":"NCT01981811","phase":"PHASE2","title":"Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder","status":"WITHDRAWN","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2014-03","conditions":"Bipolar 1 Disorder, Schizophrenia, Mental Disorder","enrollment":""},{"nctId":"NCT01509053","phase":"PHASE3","title":"Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2012-01","conditions":"Schizophrenia","enrollment":30},{"nctId":"NCT01727700","phase":"PHASE3","title":"Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2012-11","conditions":"Tourette's Disorder, Tic Disorder","enrollment":133},{"nctId":"NCT01822730","phase":"PHASE4","title":"A Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis","status":"COMPLETED","sponsor":"Wei Hao","startDate":"2013-02","conditions":"Methamphetamine Dependence","enrollment":120},{"nctId":"NCT00239356","phase":"PHASE3","title":"Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2003-03","conditions":"Schizophrenia","enrollment":119},{"nctId":"NCT01592201","phase":"PHASE4","title":"A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug","status":"TERMINATED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2012-07","conditions":"Schizophrenia","enrollment":13},{"nctId":"NCT00345033","phase":"PHASE4","title":"Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2005-03","conditions":"Schizophrenia, Insulin Resistance","enrollment":38},{"nctId":"NCT02137616","phase":"NA","title":"Antipsychotic to Treat Psychosis Syndrome","status":"UNKNOWN","sponsor":"Central South University","startDate":"2012-06","conditions":"Psychotic Disorders","enrollment":300},{"nctId":"NCT01227668","phase":"PHASE4","title":"Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-03","conditions":"Irritability Associated With Autistic Disorder","enrollment":215},{"nctId":"NCT00216476","phase":"PHASE3","title":"A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2004-10","conditions":"Schizophrenia, Psychotic Disorders","enrollment":753},{"nctId":"NCT00910780","phase":"PHASE2, PHASE3","title":"Metabolic Effects of Antipsychotic Substitution in Children","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2009-11","conditions":"Diabetes","enrollment":""},{"nctId":"NCT02069977","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of Aripiprazole","status":"UNKNOWN","sponsor":"Yoo-Sook Joung","startDate":"2014-02","conditions":"Autism","enrollment":79},{"nctId":"NCT00606320","phase":"PHASE3","title":"A Multicenter, Investigative Study of the Safety and Efficacy of Extended Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2008-01","conditions":"Bipolar I Disorder","enrollment":59},{"nctId":"NCT00606177","phase":"PHASE3","title":"A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2008-01","conditions":"Bipolar I Disorder","enrollment":99},{"nctId":"NCT01870999","phase":"PHASE1","title":"A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2007-11","conditions":"Schizophrenia","enrollment":41},{"nctId":"NCT00508157","phase":"PHASE4","title":"A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2007-11","conditions":"Metabolic Syndrome, Schizophrenia","enrollment":125},{"nctId":"NCT01438060","phase":"PHASE3","title":"Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2000-08","conditions":"Dementia, Alzheimer Type","enrollment":232},{"nctId":"NCT00665366","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2008-06","conditions":"Bipolar Disorder Mania","enrollment":493},{"nctId":"NCT00277212","phase":"PHASE4","title":"A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-12","conditions":"Bipolar Disorder","enrollment":1169},{"nctId":"NCT00857818","phase":"PHASE3","title":"Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2009-04","conditions":"Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder","enrollment":64},{"nctId":"NCT00337571","phase":"PHASE3","title":"Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-06","conditions":"Behavioral Symptoms, Autistic Disorder","enrollment":218},{"nctId":"NCT00105196","phase":"PHASE3","title":"A Study of Aripiprazole in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-03","conditions":"Major Depressive Disorder","enrollment":349},{"nctId":"NCT00365859","phase":"PHASE3","title":"Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-09","conditions":"Autistic Disorder, Behavioral Symptoms","enrollment":330},{"nctId":"NCT00332241","phase":"PHASE3","title":"Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-06","conditions":"Autistic Disorder","enrollment":98},{"nctId":"NCT00095758","phase":"PHASE3","title":"A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-09","conditions":"Major Depressive Disorder","enrollment":1200},{"nctId":"NCT00095823","phase":"PHASE3","title":"A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-06","conditions":"Major Depressive Disorder","enrollment":1200},{"nctId":"NCT00080327","phase":"PHASE4","title":"Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2003-11","conditions":"Schizophrenia","enrollment":370},{"nctId":"NCT00080314","phase":"PHASE3","title":"Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-01","conditions":"Bipolar Disorder","enrollment":400},{"nctId":"NCT00094432","phase":"PHASE3","title":"A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-06","conditions":"Bipolar I Disorder","enrollment":650},{"nctId":"NCT00082199","phase":"PHASE4","title":"Study of Aripiprazole in Subjects With Alcoholism","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-04","conditions":"Alcoholism","enrollment":400},{"nctId":"NCT00097266","phase":"PHASE3","title":"Study of Aripiprazole in Patients With Acute Bipolar Mania","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-12","conditions":"Bipolar Disorder","enrollment":615},{"nctId":"NCT00095810","phase":"PHASE4","title":"Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2003-07","conditions":"Parkinson's Disease, Psychoses","enrollment":50},{"nctId":"NCT00361790","phase":"PHASE1","title":"Aripiprazole and Lexapro Drug Interaction Study","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-08","conditions":"Healthy","enrollment":25},{"nctId":"NCT00237913","phase":"PHASE3","title":"Schizophrenia Trial of Aripiprazole","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-07","conditions":"Schizophrenia","enrollment":700},{"nctId":"NCT00095745","phase":"PHASE3","title":"A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-09","conditions":"Major Depressive Disorder","enrollment":1002},{"nctId":"NCT00321516","phase":"PHASE1","title":"Drug-drug Interaction Study of Aripiprazole and Lamotrigine in Patients With Bipolar Type I Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-07","conditions":"Bipolar Disorder","enrollment":20},{"nctId":"NCT00232687","phase":"PHASE4","title":"A Switch Study of BMS-337039 in Schizophrenic Out-patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-06","conditions":"Schizophrenia","enrollment":450},{"nctId":"NCT00101569","phase":"PHASE3","title":"Aripiprazole Oral Acceptability Trial","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-03","conditions":"Schizophrenia","enrollment":59},{"nctId":"NCT00329810","phase":"PHASE4","title":"Effect on Cognitive Function of a Treatment With Aripiprazole","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-03","conditions":"Schizophrenia","enrollment":500},{"nctId":"NCT00712686","phase":"PHASE3","title":"Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2000-06","conditions":"Schizophrenia","enrollment":690},{"nctId":"NCT00325689","phase":"PHASE4","title":"Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-07","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":323},{"nctId":"NCT00300846","phase":"PHASE4","title":"A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-12","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT00362271","phase":"PHASE1","title":"Aripiprazole and Effexor XR Drug Interaction Study","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-08","conditions":"Healthy","enrollment":38},{"nctId":"NCT00338273","phase":"PHASE3","title":"A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode","status":"WITHDRAWN","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-12","conditions":"Bipolar Disorder","enrollment":""},{"nctId":"NCT01001702","phase":"PHASE3","title":"Oral Aripiprazole Open-Label Rollover Study","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-04","conditions":"Schizophrenia","enrollment":85},{"nctId":"NCT00706654","phase":"PHASE3","title":"Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2008-09","conditions":"Schizophrenia","enrollment":937},{"nctId":"NCT01607762","phase":"PHASE1","title":"A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-02","conditions":"Healthy","enrollment":31},{"nctId":"NCT01207414","phase":"PHASE4","title":"Switching to Iloperidone From Other Antipsychotics in Schizophrenia","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-08","conditions":"Schizophrenia","enrollment":501},{"nctId":"NCT00802100","phase":"PHASE4","title":"Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2008-12","conditions":"Schizophrenia","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aripiprazole TAB","Aripiprazole OS","Abilify","Aripiprazole"],"phase":"marketed","status":"active","brandName":"Aripiprazole tablet","genericName":"Aripiprazole tablet","companyName":"All India Institute of Medical Sciences, Bhubaneswar","companyId":"all-india-institute-of-medical-sciences-bhubaneswar","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and an antagonist at serotonin 5-HT2A receptors, which stabilizes dopamine and serotonin neurotransmission in the brain. Used for Schizophrenia, Bipolar I disorder (acute manic or mixed episodes), Major depressive disorder (adjunctive treatment).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}